{
    "clinical_study": {
        "@rank": "159820", 
        "acronym": "MidPBPK", 
        "arm_group": {
            "arm_group_label": "Midazolam", 
            "description": "Patients will be enrolled within 24h from the beginning of continuous Midazolam perfusion.\nBlood and urine sampling will follow this schedule:\n24h: blood (3ml)\n48h: blood (3ml) and urine\nEnd of infusion: blood (3ml)\n6h after end of infusion: blood (3ml) and urine.\nBlood samples will be centrifuged for 10 minutes at 3300rpm, then supernatant will be placed into test tubes and stored at -20\u00b0C; urine samples will be freeze at -20\u00b0C as well.\nThen all frozen samples will be analyzed to get Midazolam concentrations."
        }, 
        "biospec_descr": {
            "textblock": "serum and urine"
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "This study investigates what independent variables may influence Midazolam Pharmacokinetics\n      in critically ill patients."
        }, 
        "brief_title": "Midazolam Whole Body Physiologically Based Pharmacokinetic Model", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Respiratory Failure", 
            "Coma"
        ], 
        "condition_browse": {
            "mesh_term": "Respiratory Insufficiency"
        }, 
        "detailed_description": {
            "textblock": "This study has three specific aims:\n\n        1. to create a Midazolam PBPK model based on anthropometric and physiopathological data\n           from enrolled patients;\n\n        2. to estimate cerebral and systemic Midazolam concentrations;\n\n        3. to assess independent variables about Midazolam pharmacokinetic in critically ill\n           patients."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  ICU admittance\n\n          -  Caucasian\n\n          -  Clinical indication of least 72h of continuous sedation with Midazolam\n\n          -  MAP between 60 - 150 mmHg, even if obtained with amine support\n\n          -  informed consent obtained\n\n        Exclusion Criteria:\n\n          -  Any endocranial lesion, spontaneous or induced\n\n          -  PaCO2 > 60 mmHg or < 30 mmHg\n\n          -  PaO2 < 50 mmHg\n\n          -  Pregnancy\n\n          -  Anuria\n\n          -  Any transplantation\n\n          -  Severe hepatic failure (Child C)\n\n          -  Life expectancy < 72h\n\n          -  Ketoconazole and antiretrovirals in therapy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Critically ill patients in Intensive Care Unit, mechanically ventilated, sedated with\n        midazolam, intravenous continued perfusion."
            }
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01973894", 
            "org_study_id": "724"
        }, 
        "intervention": {
            "arm_group_label": "Midazolam", 
            "description": "Blood and urine sampling will follow this schedule:\n24h: blood (3ml)\n48h: blood (3ml) and urine\nEnd of infusion: blood (3ml)\n6h after end of infusion: blood (3ml) and urine. Blood samples will be centrifuged for 10 minutes at 3300rpm, then supernatant will be placed into test tubes and stored at -20\u00b0C; urine samples will be freeze at -20\u00b0C as well.\nThen all frozen samples will be analyzed to get Midazolam concentrations.", 
            "intervention_name": "Blood and urine sampling", 
            "intervention_type": "Procedure"
        }, 
        "intervention_browse": {
            "mesh_term": "Midazolam"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "PBPK", 
            "Midazolam", 
            "Pharmacokinetics", 
            "Critically ill patients"
        ], 
        "lastchanged_date": "October 25, 2013", 
        "location": {
            "contact": {
                "email": "paolo.severgnini@uninsubria.it", 
                "last_name": "Paolo Severgnini, Prof.", 
                "phone": "0039.0332.278801"
            }, 
            "facility": {
                "address": {
                    "city": "Varese", 
                    "country": "Italy", 
                    "zip": "21100"
                }, 
                "name": "Azienda Ospedaliera Ospedale di Circolo e Fondazione Macchi"
            }, 
            "investigator": {
                "last_name": "Francesco Scaglione, Prof.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_groups": "1", 
        "official_title": "Whole Body Physiologically Based Pharmacokinetic (PBPK) Model to Estimate Cerebral and Systemic Midazolam Concentrations in ICU Patients Under Sedation.", 
        "overall_contact": {
            "email": "paolo.severgnini@uninsubria.it", 
            "last_name": "Paolo Severgnini, Prof.", 
            "phone": "0039.0332.278801"
        }, 
        "overall_contact_backup": {
            "last_name": "Giscardo F. Panzavolta, DM, PhD"
        }, 
        "overall_official": {
            "affiliation": "Universit\u00e0 degli Studi dell'Insubria, Varese, Italy", 
            "last_name": "Paolo Severgnini, Prof.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Italy: National Institute of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "We will calculate Midazolam AUC in serum and urine using blood and urine samples.  With this data we will evaluate the elimination constants and create a Physiologically Based Pharmacokinetic Model for Midazolam simulating the drug concentration profile in brain and fat tissue.\nThe blood and urine samples timing is:\n1 blood sample will be gathered after 24h at the beginning of continuous intravenous infusion of Midazolam\n1 blood sample and 1 urine sample will be gathered after 48h at the beginning of continuous intravenous infusion of Midazolam\n1 blood sample will be gathered at the end of continuous intravenous infusion of Midazolam (the duration of infusion is different for each patient according with clinical case)\n1 blood sample and 1 urine sample will be gathered after 6h at the end of continuous intravenous infusion of Midazolam (the duration of infusion is different for each patient according with clinical case)", 
            "measure": "Midazolam concentration in serum and urine", 
            "safety_issue": "Yes", 
            "time_frame": "Participants will be followed for the duration of hospital stay, an expected average of 3 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01973894"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Universit\u00e0 degli Studi dell'Insubria", 
            "investigator_full_name": "Paolo Severgnini", 
            "investigator_title": "Prof.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "At enrollment we will collect data about fat mass in our population. Our goal is to determine how much this variable can modify the distribution of Midazolam in the body. Statistical analysis will performed to found if different body mass values are correlated with different blood concentration of Midazolam at steady level.", 
            "measure": "Fat mass analysis and its importance in drug distribution.", 
            "safety_issue": "Yes", 
            "time_frame": "At enrollment"
        }, 
        "source": "Universit\u00e0 degli Studi dell'Insubria", 
        "sponsors": {
            "collaborator": {
                "agency": "University of Milan", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Universit\u00e0 degli Studi dell'Insubria", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "October 2013"
    }
}